Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Dec 18;7(1):17741.
doi: 10.1038/s41598-017-17437-4.

Safety and Efficacy of Losartan 50 mg in Reducing Blood Pressure among Patients with Post-Dialysis Euvolemic Hypertension: A Randomized Control Trial

Raja Ahsan Aftab  1   2 , Amer Hayat Khan  3 , Azreen Syazril Adnan  4 , Syed Azhar Syed Sulaiman  5 , Tahir Mehmood Khan  6   7
Affiliations
Randomized Controlled Trial

Safety and Efficacy of Losartan 50 mg in Reducing Blood Pressure among Patients with Post-Dialysis Euvolemic Hypertension: A Randomized Control Trial

Raja Ahsan Aftab et al. Sci Rep. .

Abstract

The aim of current study was to assess the effectiveness of losartan 50 mg in reducing blood pressure among post-dialysis euvolemic hypertensive patients, observing their survival trends and adverse events during the course of study. A multicentre, prospective, randomised, single-blind trial was conducted to assess the effect of losartan 50 mg every other day (EOD), once a morning (OM) among post-dialysis euvolemic hypertensive patients. Post-dialysis euvolemic assessment was done by a body composition monitor (BCM). Covariate Adaptive Randomization was used for allocation of participants to the standard or intervention arm. Of the total 229 patients, 96 (41.9%) were identified as post-dialysis euvolemic hypertensive. Final samples of 88 (40.1%) patients were randomized into standard and intervention arms. After follow-up of 12 months' pre-dialysis systolic (p < 0.001) and diastolic (p 0.01), intradialysis diastolic (p 0.02), post-dialysis systolic (p < 0.001) and diastolic (p < 0.001) blood pressure was reduced from the baseline among intervention-arm patients Compared to only pre-dialysis systolic blood pressure (p 0.003) among standard arm patients after 12 months of follow. Total of six deaths were reported among standard-arm patients compared to 2 deaths among the intervention arm. Losartan 50 mg achieve an overall significant decline in blood pressure among post-dialysis euvolemic hypertensive patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Selection of euvolemic hypertensive patients.
Figure 3
Figure 3
Study arm based survival analysis of study subjects.
Figure 4
Figure 4
Gender based survival analysis of study subjects.
See this image and copyright information in PMC

References

    1. Foley RN, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephro. 2005;6(2):489–95. doi: 10.1681/ASN.2004030203. - DOI - PubMed
    1. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis. 2008;51(1 suppl 1):S1–320. - PubMed
    1. Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int. 2002;61(2):717–26. doi: 10.1046/j.1523-1755.2002.00173.x. - DOI - PubMed
    1. Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol. 2011;34(4):381–90. doi: 10.1159/000331067. - DOI - PMC - PubMed
    1. D’Amico M, Locatelli F. Hypertension in dialysis: pathophysiology and treatment. J Nephrol. 2002;15:438–45. - PubMed

Publication types

Substances